KMTS Stock Forecast: Kestra Medical Technologies Ltd. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Kestra Medical Technologies Ltd. hold a median 12-month price target of $31 — +23.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kestra Medical Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (74): The shares have been drifting up relative to others.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KMTS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KMTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Evercore ISI Group | Initiates | Outperform | $34 |
| 15 Sept 2026 | BTIG | Reiterates | Buy | $32 |
| 2 Sept 2026 | BTIG | Reiterates | Buy | $32 |
| 10 Aug 2026 | JP Morgan | Initiates | Overweight | $30 |
| 21 July 2026 | Oppenheimer | Initiates | Perform | — |
| 15 July 2026 | BTIG | Maintains | Buy | $30 → $32 |
| 9 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 7 Apr 2026 | BTIG | Reiterates | Buy | — |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 18 Mar 2026 | BTIG | Reiterates | Buy | — |
| 15 Dec 2025 | Goldman Sachs | Maintains | Neutral | — |
| 12 Dec 2025 | Piper Sandler | Maintains | Overweight | — |
| 12 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 18 Nov 2025 | BTIG | Initiates | Buy | — |
| 17 July 2025 | Wells Fargo | Maintains | Overweight | — |
| 16 Apr 2025 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2025 | Goldman Sachs | Initiates | Neutral | — |
| 31 Mar 2025 | Piper Sandler | Initiates | Overweight | — |
| 31 Mar 2025 | Stifel | Initiates | Buy | — |
| 31 Mar 2025 | Wells Fargo | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KMTS.
This page is one stock. Monday covers all of them.
KMTS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KMTS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kestra Medical Technologies Ltd. returned +0.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KMTS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 14.0×
- Price / book
- 6.7×
- EV / EBITDA
- —
Cheaper than 9% of US stocks
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 54.8%
- Operating margin
- —
- Net margin
- —
Higher than 67% of US stocks
- Return on equity
- −73.7%
- Return on assets
- −29.2%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kestra Medical Technologies Ltd. has a market value of $1.5B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 Apr 2026: $95.1M. The latest quarter grew 66.2% year on year.
Net income over the same four quarters: −$131.6M, a −138.4% net margin.
Diluted earnings per share, trailing twelve months: −$2.42.
Free cash flow in the twelve months to 30 Apr 2026: −$117.1M, after $35.4M of capital spending.
Kestra Medical Technologies Ltd. spent $323K on dividends in the twelve months to 30 Apr 2026.
Kestra Medical Technologies Ltd. employs 443 people — $215K of revenue per employee.
Data provided by Twelve Data
KMTS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KMTS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kestra Medical Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KMTS
What is the KMTS stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Kestra Medical Technologies Ltd. have a median 12-month price target of $31, with estimates ranging from $28 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KMTS stock a buy right now?
Of the 9 analysts covering Kestra Medical Technologies Ltd., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kestra Medical Technologies Ltd. 27 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KMTS?
As at 21 Nov 2026, Kestra Medical Technologies Ltd. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (74 of 100).
Will KMTS stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +23.5% from the last close, and Ticker Nerd's factor model ranks Kestra Medical Technologies Ltd. 27 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KMTS stock forecast for 2030?
No analyst covering Kestra Medical Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $34 over the next 12 months.
How has KMTS stock performed over the past year?
Kestra Medical Technologies Ltd. returned +0.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kestra Medical Technologies Ltd. do?
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular care. Kestra Medical Technologies develops and commercializes the Cardiac Recovery System, an integrated platform designed to support patients at elevated risk of sudden cardiac arrest during vulnerable recovery periods.
About Kestra Medical Technologies Ltd.
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular care. Kestra Medical Technologies develops and commercializes the Cardiac Recovery System, an integrated platform designed to support patients at elevated risk of sudden cardiac arrest during vulnerable recovery periods. Its core offering is the ASSURE Wearable Cardioverter Defibrillator, which continuously monitors heart rhythms and can deliver defibrillation therapy when life-threatening arrhythmias are detected. The company also provides connected digital tools that support patient engagement, clinical workflow, and care coordination, helping clinicians access actionable cardiac data and oversee recovery more effectively. Based in Kirkland, Washington, Kestra Medical Technologies serves the medical technology market by combining diagnostic monitoring, therapeutic intervention, and data-driven support services into a single cardiovascular care ecosystem.
CEO Mr. Brian Webster · 443 employees · United States · https://kestramedical.com